Clinical Trials
9 trialsNCT05818683 2026-06-05
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT05997615 2026-06-04
AMX-500
Vir Biotechnology, Inc.
Phase 1 Recruiting
NCT07190300 2026-06-03
TulmiSTAR-02
Novartis
Phase 1/2 Recruiting
NCT07617272 2026-06-01
PARIS-BIO
Region Stockholm
Phase 2 Recruiting
NCT07395804 2026-05-29
23146
Bayer
Recruiting
NCT07611110 2026-05-28
VECTRA-01
AstraZeneca
Phase 3 Recruiting
NCT06661122 2026-05-19
HAYATE
Bayer
Recruiting
NCT05348876 2026-05-18
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Bayer
Phase 4 Recruiting
NCT07244341 2026-05-15
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Daiichi Sankyo
Phase 1 Recruiting